Let’s call a spade a spade

Whew, glad there is no need to call the wammmbulance. The CKD stage 3 and 4 patients are out there but without 25D levels less than 30.

OUT comes the truth: The patients that were enrolled in the clinical trial (sprague) were prior to 2015. They are probably either on dialysis or dead. Bishop is peddling his pipe dream again as there has been adequate time to follow theses original patients.
Patty can not follow this timeline or do the math. We could ask the RSS who calls on Sprague who was fired 2 weeks ago or we could pack a parachute.
 






Email reaches the top floor. what are you waiting for? Go ahead and email Frosty. And while you are at it, cc Jane. She may not be dialed in. Ask them to comment on the future of this franchise without being able to sell to Medicate Part D Patients. Medicare Part D Patients can not afford and are not willing to exhaust several hundred dollars a month for their drug. (In case you are reading this, Patty)
 






Do you need a lesson on the recognition of sarcasm? The point is that there are not as many stage 3 patients and patients with commercial insurance as Patty believes. Certainly not enough to waste staff time chasing down PAP for Rayaldee when they could be finding funding for one of the many new drugs that actually have outcomes data. Speaking of outcomes data, Rayaldee has been out for four years. Why hasn’t a morbidity and mortality study been conducted? Where is the head to head study Charlie was so proud of? I’d ask Patty but she does not want to entertain the hard questions.
 






If you have a friend who thinks they work in a toxic place, take them out for drinks and share with them “a day in the life at OPKO.” They will hug you, and probably buy your drinks.
 












Unless there is a medially relevant reason where he shouldbe advocating for donati g to 501c3 or that we should be nervous about his mental health lets hear it. I am being blocked fro. Postng this